Lindenmaier H - Search Results

1

Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine.

Rengelshausen J, Lindenmaier H, Cihlar T, Walter-Sack I, Haefeli WE, Weiss J. Rengelshausen J, et al. Among authors: lindenmaier h. Biochem Biophys Res Commun. 2004 Jul 16;320(1):90-4. doi: 10.1016/j.bbrc.2004.05.142. Biochem Biophys Res Commun. 2004. PMID: 15207706

2

Interaction of antiepileptic drugs with human P-glycoprotein in vitro.

Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE. Weiss J, et al. Among authors: lindenmaier h. J Pharmacol Exp Ther. 2003 Oct;307(1):262-7. doi: 10.1124/jpet.103.054197. Epub 2003 Sep 3. J Pharmacol Exp Ther. 2003. PMID: 12954800

3

Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.

Ehrhardt M, Lindenmaier H, Burhenne J, Haefeli WE, Weiss J. Ehrhardt M, et al. Among authors: lindenmaier h. Biochem Pharmacol. 2004 Jan 15;67(2):285-92. doi: 10.1016/j.bcp.2003.09.008. Biochem Pharmacol. 2004. PMID: 14698041

4

Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells.

Troost J, Lindenmaier H, Haefeli WE, Weiss J. Troost J, et al. Among authors: lindenmaier h. Mol Pharmacol. 2004 Nov;66(5):1332-9. doi: 10.1124/mol.104.002329. Epub 2004 Aug 12. Mol Pharmacol. 2004. PMID: 15308763

5

Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?

Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V, Bergk V, Haefeli WE. Martin-Facklam M, et al. Among authors: lindenmaier h. Eur J Clin Pharmacol. 2005 Jan;60(11):807-11. doi: 10.1007/s00228-004-0852-y. Epub 2004 Dec 14. Eur J Clin Pharmacol. 2005. PMID: 15599503

6

Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2).

Lindenmaier H, Becker M, Haefeli WE, Weiss J. Lindenmaier H, et al. Drug Metab Dispos. 2005 Nov;33(11):1576-9. doi: 10.1124/dmd.105.005314. Epub 2005 Jul 27. Drug Metab Dispos. 2005. PMID: 16049127

7

Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.

Peters T, Lindenmaier H, Haefeli WE, Weiss J. Peters T, et al. Among authors: lindenmaier h. Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):291-9. doi: 10.1007/s00210-005-0022-5. Epub 2005 Dec 20. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16365780

8

Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.

Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Weiss J, et al. Among authors: lindenmaier h. Drug Metab Dispos. 2007 Mar;35(3):340-4. doi: 10.1124/dmd.106.012765. Epub 2006 Dec 15. Drug Metab Dispos. 2007. PMID: 17172311

9

Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Storch CH, et al. Among authors: lindenmaier h. Biochem Pharmacol. 2007 May 15;73(10):1573-81. doi: 10.1016/j.bcp.2007.01.027. Epub 2007 Jan 24. Biochem Pharmacol. 2007. PMID: 17328866

10

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.

Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, Schnabel PA, Schirmacher P, Hoffmann H, Muley T, Weichert W. Warth A, et al. Among authors: lindenmaier h. Eur Respir J. 2014 Mar;43(3):872-83. doi: 10.1183/09031936.00018013. Epub 2013 Aug 29. Eur Respir J. 2014. PMID: 23988776 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters